經直腸超音波導引前列腺切片之病理結果及併發症
詹鎮豪1、黃書彬1,2、李經家1,2、黃琮懿1,2、柯宏龍1,2、黃俊農1,2、周以和1,2、溫聖辰1,2
1高雄醫學大學附設醫院 泌尿部
2高雄醫學大學 醫學系
Outcomes and complications after transrectal ultrasound-guided prostate biopsy: A single-center study involving 425 consecutive patients
Jhen-Hao Jhan1, Shu-Pin Huang1,2, Ching-Chia Li1,2, Tsung-Yi Huang1,2, Hung-lung Ke1,2, Chun-Nung Huang1,2, Yii-Her Chou1,2, Shen-Chen Wen1,2
1Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
2Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
Objective: The use of 10–12-core systemic transrectal ultrasound (TRUS)-guided prostate biopsy protocols with extended-sampling, has been an optimizing strategy for diagnosis of prostate cancer. In this study, we aim to examine the cancer detection rate (CDR) and the complications following prostate biopsy at our institution.
Materials and methods: We retrospectively reviewed medical data of patients who underwent TRUS-guided prostate biopsy between 2007 and 2013 at our institution. The pathological outcomes, major complications, and morbidities were recorded and assessed clinically.
Results: During the study period, 425 patients who underwent TRUS-guided prostate biopsy were enrolled. The mean age of the participants was 67.9 years. Overall, 75 (17.6%) patients were diagnosed with prostate cancer. Cancer was detected in 51.3% (40/78), 16.7% (20/120), 6.9% (15/217), and 0% (0/10) of patients in the subgroups with patient PSA >20 ng/m, 10–20 ng/ml, 4–10 ng/ml, and <4 ng/ml, respectively. In total, 11 patients had afebrile urinary tract infections (UTI), 9 patients had febrile UTI, and another 2 patients had septic shock after biopsy. The overall incidence of infectious complications was 5.17% (22/425). Other complications were infrequent, consisting only of urinary retention in 3 patients, hematospermia in 2 patients, and acute hemorrhagic cerebellar infarction in 1 patient.
Conclusions: Our study demonstrated the CDR, the incidence, and type of complications following TRUS-guided prostate biopsy. Further prospective studies are required to determine methods for reducing complications from prostate biopsy.